10x Genomics Dirección
Dirección controles de criterios 4/4
El CEO de 10x Genomics' es Serge Saxonov , nombrado en Jul 2012, tiene una permanencia de 11.75 años. compensación anual total es $18.81M, compuesta por 2.7% salario y 97.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 3.36% de las acciones de la empresa, por valor de $110.31M. La antigüedad media del equipo directivo y de la junta directiva es de 6.1 años y 6.7 años, respectivamente.
Información clave
Serge Saxonov
Chief Executive Officer (CEO)
US$8.3m
Compensación total
| Porcentaje del salario del CEO | 6.6% |
| Permanencia del CEO | 11.8yrs |
| Participación del CEO | 3.3% |
| Permanencia media de la dirección | 6.2yrs |
| Promedio de permanencia en la Junta Directiva | 6.8yrs |
Actualizaciones recientes de la dirección
Recent updates
Why We're Not Concerned About 10x Genomics, Inc.'s (NASDAQ:TXG) Share Price
Apr 15
Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Feb 0510x Genomics: Sales Are Growing At A Rapid Rate, But So Are Expenses
Jan 20Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%
Dec 22We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely
Nov 03Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Aug 04Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S
Jun 04At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?
Apr 2910x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate
Mar 24We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow
Feb 02Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?
Jan 12An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued
Dec 2210x Genomics: No Signs Of A Growth Turnaround, Heavy Bearish Momentum
Oct 12Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Oct 0510x Genomics cut to Sell at Goldman Sachs on slower sales ramp
Aug 1810x Genomics: Still Expensive, No Profitability In Sight, And Insiders Are Still Selling
Jul 3010x Genomics guides to Q2 revenues below consensus; shares down 13% after hours
Jul 14Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$264m |
| Dec 31 2023 | US$8m | US$545k | -US$255m |
| Sep 30 2023 | n/a | n/a | -US$223m |
| Jun 30 2023 | n/a | n/a | -US$172m |
| Mar 31 2023 | n/a | n/a | -US$174m |
| Dec 31 2022 | US$19m | US$504k | -US$166m |
| Sep 30 2022 | n/a | n/a | -US$167m |
| Jun 30 2022 | n/a | n/a | -US$142m |
| Mar 31 2022 | n/a | n/a | -US$89m |
| Dec 31 2021 | US$12m | US$430k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$455m |
| Jun 30 2021 | n/a | n/a | -US$504m |
| Mar 31 2021 | n/a | n/a | -US$533m |
| Dec 31 2020 | US$11m | US$400k | -US$543m |
| Sep 30 2020 | n/a | n/a | -US$134m |
| Jun 30 2020 | n/a | n/a | -US$78m |
| Mar 31 2020 | n/a | n/a | -US$49m |
| Dec 31 2019 | US$2m | US$394k | -US$31m |
| Sep 30 2019 | n/a | n/a | -US$100m |
| Jun 30 2019 | n/a | n/a | -US$105m |
| Mar 31 2019 | n/a | n/a | -US$105m |
| Dec 31 2018 | US$1m | US$366k | -US$112m |
Compensación vs. Mercado: La compensación total ($USD8.29M) de Serge está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD6.67M).
Compensación vs. Ingresos: La compensación de Serge ha sido consistente con los resultados de la empresa en el último año.
CEO
Serge Saxonov (46 yo)
11.8yrs
Permanencia
US$8,286,050
Compensación
Dr. Serge Saxonov, Ph D, Co-Founded 10X Genomics, Inc. and has been its Chief Executive Officer and Director since July 2012. Prior to 10x Genomics, Dr. Saxonov was Vice President of Applications at Quanta...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 11.8yrs | US$8.29m | 3.35% $ 105.8m | |
| Co-Founder | 11.8yrs | US$4.43m | 2.56% $ 80.8m | |
| Chief Financial Officer | 5.6yrs | US$3.31m | 0.042% $ 1.3m | |
| Chief Legal Officer | 6.8yrs | US$3.88m | 0.12% $ 3.7m | |
| Founding Scientist & CTO | 2.3yrs | sin datos | sin datos | |
| Manager of Investor Relations and Strategic Finance | no data | sin datos | sin datos | |
| Chief People Officer | 3.3yrs | sin datos | sin datos | |
| Associate Director of Product Management | no data | sin datos | sin datos |
6.2yrs
Permanencia media
47.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de TXG es experimentado (6.1 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 11.8yrs | US$8.29m | 3.35% $ 105.8m | |
| Co-Founder | 11.8yrs | US$4.43m | 2.56% $ 80.8m | |
| Independent Director | 4.2yrs | US$338.71k | 0.0035% $ 109.3k | |
| Independent Chairman | 10.8yrs | US$403.59k | 2.05% $ 64.7m | |
| Independent Director | 4.8yrs | US$336.39k | 0.0035% $ 109.3k | |
| Independent Director | 6.8yrs | US$331.39k | 0.14% $ 4.5m | |
| Independent Director | 5.1yrs | US$346.39k | 0.029% $ 923.1k |
6.8yrs
Permanencia media
51yo
Promedio de edad
Junta con experiencia: La junta directiva de TXG se considera experimentada (6.7 años de antigüedad promedio).